Trinity Biotech (TRIB) Net Margin (2009 - 2024)

Trinity Biotech has disclosed Net Margin across 16 years of filings, most recently posting 99.62% for Q4 2024.

• Net Margin for Q4 2024 came in at 99.62%, down 5865.0% year-over-year; the trailing twelve-month figure through Dec 2024 was 50.02% (up 1486.0% YoY), and the FY2025 annual result was 85.36%, down 3372.0% from the prior year.
• Net Margin came in at 99.62% for Q4 2024 at Trinity Biotech, down from 31.64% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 33.5% in Q3 2020 to a low of 131.93% in Q2 2023.
• The 5-year median for Net Margin is 36.31% (2024), against an average of 31.98%.
• Across the five-year window, Net Margin plunged 10151 bps in 2022 and jumped 8805 bps in 2024, its largest moves.
• Trinity Biotech's Net Margin stood at 27.84% in 2020, then sank by 165 bps to 17.99% in 2021, then plunged by 255 bps to 63.95% in 2022, then surged by 36 bps to 40.97% in 2023, then plunged by 143 bps to 99.62% in 2024.
• The last three Net Margin figures came in at 99.62% (Q4 2024), 31.64% (Q3 2024), and 43.88% (Q2 2024), per Business Quant data.